{
  "report_rows": [
    {
      "kpi": "Product sales excluding Veklury",
      "prediction": "BEAT",
      "answer": "pred ~$7.23B vs. cons $7.13B.",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Yeztugo sales",
      "prediction": "BEAT",
      "answer": "pred ~$235M vs. cons $220M.",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Trodelvy sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$415M vs. cons $411M.",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 product sales",
      "prediction": "UNCHANGED",
      "answer": "guide ~$30.20B vs. cons $30.20B (FY26).",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 Yeztugo sales",
      "prediction": "LOWER",
      "answer": "guide ~$1.00B vs. cons $1.05B (FY26).",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 reported non-GAAP EPS",
      "prediction": "LOWER",
      "answer": "guide ~$(0.85) vs. cons ~$(0.75) (FY26).",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.3,
  "day5_path": "FADE",
  "day5_rationale": "A ~+$1.5% day-1 residual should fade toward ~+0.3% by day 5: a Yeztugo/product-sales beat supports the initial move, but unchanged $30.20B sales guidance and retained ~$1.00B Yeztugo outlook leave FY26/FY27 revenue and normalized-EPS estimates without enough upward revision for sustained follow-through.",
  "day5_confidence": "MEDIUM"
}